2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Alison Walker: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia HDAC inhibitor AR-42, decitabine, laboratory biomarker analysis - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Alison Walker | 13 | 2013-09-17 | 2018-03-14 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia midostaurin, Bortezomib, mitoxantrone hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following | Phase 1 | Completed | Alison Walker | 34 | 2010-08-01 | 2016-07-06 |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes lintuzumab, 5-azacytidine - Leukemia, Myelodysplastic Syndromes | Phase 2 | Terminated | Alison Walker | 7 | 2009-11-01 | 2017-05-10 |
Congenital Abnormalities (2) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1)
Azacitidine (1) · Bortezomib (1) · Cytarabine (1) · Decitabine (1) · Etoposide (1) · HDAC-42 (1) · Mitoxantrone (1) · Podophyllotoxin (1) · lintuzumab (1) · midostaurin (1)
United States (3)